Zobrazeno 1 - 9
of 9
pro vyhledávání: '"M E J, Reinders"'
Autor:
B. Hezer, M. E. J. Reinders, M. W. F. van den Hoogen, M. Tielen, J. van de Wetering, D. A. Hesselink, E. K. Massey
Publikováno v:
Transplant International, Vol 37 (2024)
After transplantation self-management is essential for graft survival and optimal quality of life. To address the need for home-based support in self-management, we implemented the “SelfCare after Renal Transplantation” (SeCReT) box, containing h
Externí odkaz:
https://doaj.org/article/4565e24a0c5b4dc29de059552a8c92c5
Autor:
G. van der Elst, H. Varol, M. Hermans, C. C. Baan, J. P. Duong-van Huyen, D. A. Hesselink, R. Kramann, M. Rabant, M. E. J. Reinders, J. H. von der Thüsen, T. P. P. van den Bosch, M. C. Clahsen-van Groningen
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/66eeb3fac9fd440caacadcc7847d99cf
Autor:
P. Bouwmans, A. L. Messchendorp, J. S. Sanders, L. Hilbrands, M. E. J. Reinders, P. Vart, F. J. Bemelman, A. C. Abrahams, M. A. van den Dorpel, M. A. Ten Dam, A. P. J. de Vries, T. Rispens, M. Steenhuis, R. T. Gansevoort, M. H. Hemmelder, RECOVAC Collaborators
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background COVID-19 is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD) stages G4-G5, on dialysis or after kidney transplantation (kidney replacement therapy, KRT). SARS-CoV-2 vaccine trials do
Externí odkaz:
https://doaj.org/article/db49c9e3f51e4744ab4bb295e6b08127
Autor:
G. van der Elst, H. Varol, M. Hermans, C. C. Baan, J. P. Duong-van Huyen, D. A. Hesselink, R. Kramann, M. Rabant, M. E. J. Reinders, J. H. von der Thüsen, T. P. P. van den Bosch, M. C. Clahsen-van Groningen
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Mast cells (MCs) are innate immune cells with a versatile set of functionalities, enabling them to orchestrate immune responses in various ways. Aside from their known role in allergy, they also partake in both allograft tolerance and rejection throu
Externí odkaz:
https://doaj.org/article/9fddadb5cf5a4cc5a385c49adaca02bc
Autor:
T. Tramper, D. L. Roelen, S. H. Brand-Schaaf, J. A. Kal-van Gestel, M. M. L. Kho, M. E. J. Reinders, J. I. Roodnat, J. van de Wetering, M. G. H. Betjes, A. E. de Weerd
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
BackgroundThe impact of donor-specific antibodies (DSA) in (highly-) immunized living donor kidney transplant recipients is reported differentially in various patient cohorts.MethodsWe have performed a retrospective analysis of all consecutive HLA-in
Externí odkaz:
https://doaj.org/article/edf15d26e0914e6fadd9da4b408250d7
Autor:
J, Vos, H, Tejeda-Mora, A, Merino, L, Wu, W W, Woud, J A A, Demmers, W F J, van IJcken, M E J, Reinders, M J, Hoogduijn
Publikováno v:
Journal of Controlled Release, 350, 642-651. Elsevier
Vesicle-based medicines hold great promise for therapy development but essential knowledge on the bio-distribution and longevity of vesicles after administration is lacking. We generated vesicles from the membranes of human mesenchymal stromal cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::407dd187d77c30738b6bfb8c3726e620
https://doi.org/10.1016/j.jconrel.2022.08.060
https://doi.org/10.1016/j.jconrel.2022.08.060
Autor:
M C Meucci, M E J Reinders, K E Groeneweg, S Bezstarosti, N Ajmone Marsan, J J Bax, J W De Fijter, V Delgado
Publikováno v:
European Heart Journal. 43
Background After renal transplantation, there is a need for immunosuppressive regimens that effectively prevent allograft rejection, while minimizing cardiovascular side effects. The TRITON study is the first randomized clinical trial that tested a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2aa8d57d16870725d9287465f1f7944
https://doi.org/10.1093/eurheartj/ehac544.2616
https://doi.org/10.1093/eurheartj/ehac544.2616
Publikováno v:
Journal of Immunology Research, Vol 2015 (2015)
Despite excellent short-term graft survival after renal transplantation, the long-term graft outcome remains compromised. It has become evident that a combination of sustained alloreactivity and calcineurin-inhibitor- (CNI-) related nephrotoxicity re
Externí odkaz:
https://doaj.org/article/fd76cd70e986465b8c639336185cd43a
Autor:
R, Ter Heine, N P, van Erp, H J, Guchelaar, J W, de Fijter, M E J, Reinders, C M, van Herpen, D M, Burger, D J A R, Moes
Publikováno v:
British journal of clinical pharmacology. 84(7)
AIMS: Everolimus is a drug from the class of mammalian target of rapamycin inhibitors used for both immunosuppressant and oncological indications. We postulate that there is room for improvement of dosing, as the optimal immunosuppressive dose in cal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7354c23f4ac7ccb3b09da1a96fa12691
https://pubmed.ncbi.nlm.nih.gov/29574974
https://pubmed.ncbi.nlm.nih.gov/29574974